Background: Given the relatively high prevalence of recurrent and persistent acute otitis media (AOM) and the prominent etiologic role of Streptococcus pneumoniae, especially penicillin-nonsusceptible strains in children with these conditions, new alternative treatments are desirable. Methods: Children 6 months-4 years of age with AOM considered to be at risk for recurrent or persistent infection received large dosage cefdinir 25 mg/kg oral suspension once daily for 10 days. Children were evaluated pretreatment (day 1), on therapy (days 4 -6), end of therapy (days 12-14) and at follow-up (days 25-28). All children had tympanocentesis at enrollment. In culture-positive children, tympanocentesis was repeated after 3-5 days (days 4 -6) unless evidence of absence of middle ear effusion was documented. Results: Of 447 children enrolled, 230 were clinically and bacteriologically evaluable (74% 2 years old or younger; 57% treated for AOM in previous 3 months). Bacteriologic eradication, based on repeat tympanocentesis on days 4 -6, was achieved in 74% (170 of 230) of children; 76% (201 of 266) of AOM pathogens were eradicated. Eradication of penicillin-susceptible, -intermediate and -resistant S. pneumoniae was 91% (50 of 55), 67% (18 of 27) and 43% (10 of 23), respectively (P Ͻ 0.001); eradication of H. influenzae was 72% (90 of 125). Overall clinical response at days 12-14 was 83% (76 and 82% for children with S. pneumoniae and Haemophilus influenzae, respectively). Sustained clinical response at days 25-28 was 85%. Clinical response was 83% for culturepositive children versus 96% for culture-negative children at baseline tympanocentesis (P Ͻ 0.001). Conclusions: In this study of AOM among children at risk for persistent or recurrent infection, large dose cefdinir resulted in an overall successful clinical response at end of treatment of 83%. This regimen was efficacious against penicillin-susceptible S. pneumoniae, but effectiveness was markedly decreased against nonsusceptible strains and was moderate for H. influenzae strains.
A cute otitis media (AOM) is the most common bacterial infection of childhood, 1 with the majority (85%) of children experiencing their first episode by the time they are 12 months old. 2 Results of prospective cohort studies 3, 4 and national surveys 5, 6 suggest that ϳ10 -30% of children experience recurrent episodes of AOM during their first several years of life or are therapeutic failures. 7 This group of children poses a challenge to clinicians because of the wellknown high risk of having an antimicrobial-resistant middle ear fluid (MEF) pathogens.
The selection of an antibiotic for the treatment of children with recurrent otitis media and otitis media therapeutic failure should be based on acceptable antimicrobial activity against MEF pathogens and assurance that the selected agent achieves MEF concentrations above the minimal inhibitory concentrations (MIC) of the target pathogens and, in the case of ␤-lactam agents, the antimicrobial concentration time above the MIC should be Ն40% of the dosing interval time. 8, 9 Various microbiologic studies have shown that children with recurrent or persistent AOM are at higher risk of being infected with penicillin-nonsusceptible Streptococcus pneumoniae or ␤-lactamase-producing pathogens such as Haemophilus influenzae than children with uncomplicated AOM. 8 -14 Cefdinir is an extended spectrum cephalosporin with in vitro activity against the major pathogens causing AOM, including penicillin-susceptible (MIC 90 Ͻ 0.12 g/mL) S. pneumoniae, Streptococcus pyogenes (MIC 90 Ͻ 0.06 g/mL), ␤-lactamase-producing strains of H. influenzae (MIC 90 0.5 g/mL) and Moraxella catarrhalis (MIC 90 0.25 g/mL). 15, 16 Based on the results of previous clinical trials, cefdinir (14 mg/kg/d) administered once or twice daily was approved for the treatment of children with AOM. [17] [18] [19] [20] [21] [22] Those trials were conducted primarily in children with uncomplicated AOM, with only a minority of children having a history of recurrent infections and none of the evaluated children having refractory infections. Moreover, in the case of S. pneumoniae, cefdinir at 14 mg/kg/d was approved by the Food and Drug Administration only for the treatment of children with AOM caused by penicillin-susceptible S. pneumoniae, because ev-idence of clinical response in infections caused by penicillinnonsusceptible strains was lacking.
This double tympanocentesis study was therefore designed to evaluate the bacteriologic response during treatment, the clinical efficacy at end of treatment and the safety of large dosage cefdinir (25 mg/kg/d) in children with AOM at risk for recurrent or persistent infections, with special emphasis on eradication rate of penicillin-nonsusceptible S. pneumoniae isolates with this higher dose of cefdinir.
CHILDREN AND METHODS

Study Design
This study was a prospective, open label, multicenter (17 sites in Latin America, the United States and Israel) study that enrolled children with AOM between July 2002 and April 2003. An Institutional Review Board or Ethics Committee at each participating center reviewed and approved the protocol. Written informed consent was obtained from parents (or legal representatives) of each child before enrollment into the study.
Children
The study population consisted of children between 6 months and 4 years of age with a clinical diagnosis of AOM based on the presence of otalgia, ear fullness, decreased hearing and/or purulent discharge caused by acute perforation of the tympanic membrane, in association with at least 2 of the following conditions: bulging tympanic membrane; opacification of tympanic membrane; and/or purulent effusion behind the tympanic membrane corroborated by pneumatic otoscopy. The presence of MEF was established by tympanometry or spectral gradient acoustic reflectometry (SGAR) (Ear Check). To be eligible for study enrollment, children must also have satisfied at least 2 of the following criteria: 24 months of age or younger; antibiotic exposure for AOM within the previous 3 months; day-care attendance or siblings/household contacts 8 years of age or younger. Children who had either a ventilation tube or perforated tympanic membrane for Ͼ24 hours before enrollment were excluded.
Antimicrobial Therapy
Children were treated in an open label manner with cefdinir oral suspension (Omnicef; Abbott Laboratories) 25 mg/kg given once daily for 10 days.
Study Procedures
On day 1 (pretreatment), medical history, physical examination with an otologic assessment and hematology, chemistry and urine analyses were performed, and a sample of MEF was obtained from the affected ear(s) by tympanocentesis. Direct culture was permitted for children with ruptured membrane and purulent discharge for Ͻ24 hours.
Clinical and otoscopic (pneumatic otoscopy and tympanometry or by SGAR) assessments were conducted at all subsequent visits ͓days 4 -6 (on therapy), days 12-14 (end of treatment) and day 25-28 (end of study, follow-up)͔. Hematology, chemistry and urine testing was repeated at the endof-treatment visit and as needed thereafter if clinically significant abnormal results were detected at end of treatment.
Tympanocentesis was repeated at the on-therapy visit in children who had AOM pathogens at baseline and persistent MEF confirmed by tympanometry or SGAR. An additional tympanocentesis was recommended if a child was categorized as a clinical failure or relapse. At Children's Hospital of Pittsburgh, a repeat tympanocentesis at the ontherapy visit was performed only in those children with a baseline nonsusceptible S. pneumoniae or H. influenzae and with the following findings during the on-therapy visit: presence of MEF and otalgia plus mild bulging of the tympanic membrane or moderate to severe bulging without otalgia. Investigators evaluated children for adverse events at all visits and categorized the adverse events by severity as mild, moderate or severe and by potential relationship to study drug.
Microbiology
Culture and susceptibility testing from MEF samples were initially performed at local laboratories. Identified isolates were sent to a central laboratory ( 25 For H. influenzae, isolates with an MIC to cefdinir of Յ1 g/mL were considered susceptible. For organisms other than H. influenzae and Streptococcus spp., isolates with an MIC to cefdinir of Յ1 g/mL were considered susceptible, isolates with an MIC of 2 g/mL were considered intermediate and isolates with an MIC of Ն4 g/mL were considered resistant.
Outcome Measures
Bacteriologic response was assessed at the on-therapy visit in bacteriologically evaluable and clinically/bacteriologically evaluable populations. Children were considered bacteriologically evaluable if at least 1 target pathogen (H. influenzae, S. pyogenes, S. pneumoniae or M. catarrhalis) was isolated at baseline and a follow-up tympanocentesis or culture of draining pus was performed at the on-therapy visit or if no MEF could be aspirated at that time. To be considered clinically and bacteriologically evaluable, children must have had (1) completed at least 80% of their prescribed study drug or at least 3 days of study medication if the child was categorized as a clinical failure, (2) a target pathogen must have been isolated at baseline and (3) a clinical assessment at the end-oftreatment visit. Concurrent use of a systemic antimicrobial agent was not allowed.
The primary efficacy end point was bacteriologic eradication rate at the on-therapy visit in the bacteriologically evaluable population. Bacteriologic eradication rate was defined as the percentage of children with at least 1 target pathogen isolated from the baseline culture that had a bacteriologic response of documented or presumed eradication for the pretreatment pathogen(s) at the on-therapy visit. A child was classified as presumed eradication if no material was obtained (dry tap) at the time of the on-therapy tympanocentesis or if a second tympanocentesis was not performed because of the absence of MEF.
Secondary endpoints included clinical response rate at end of treatment and end of study among clinically and bacteriologically evaluable children. Clinical response was classified by the investigator as cure or failure at end of treatment. Clinical cure was defined as complete (cure) or partial (improvement) resolution of AOM signs and symptoms without the need for additional antimicrobials. A child was considered a clinical failure if signs and symptoms of AOM persisted after at least 72 hours of study drug and additional antimicrobial therapy for AOM was required. Sustained cure and recurrence of AOM (child previously evaluated as cured or improved at end of treatment visit who satisfied the criteria for failure between end of treatment and end of study) were assessed at end of study.
Safety
Children who received at least 1 dose of study medication were included in the safety analysis. Child safety and study drug tolerability were assessed at every visit. Treatment-related adverse events included those judged by the investigators to be probably related or possibly related to the study drug, and each event was categorized by the investigators as mild, moderate or severe. Diarrhea was defined as Ն3 watery stools/d or Ն2 watery stools/d for 2 consecutive days. Any other modification of the child's stools, referred by the parents, was classified as abnormal stools. Compliance with the study regimen was verified by parental diaries and inspection of returned medication bottles at the end-of-treatment visit.
Statistical Analyses
This study included a single treatment of children with AOM. For each efficacy variable, an overall rate and corresponding 95% confidence interval were calculated. Fisher's exact test was used to compare: child bacteriologic eradication rates and target pathogen eradication rates in children 24 months of age or younger versus 24 months of age or older; pathogen eradication rates for ␤-lactamase-positive and ␤-lactamase-negative strains of H. influenzae and for S. pneumoniae in penicillin-susceptible versus nonsusceptible strains; clinical cure rates at the end of treatment and end of study in children infected with penicillin-susceptible versus nonsusceptible strains of S. pneumoniae; and clinical cure rate at the end of treatment in children with eradication versus persistence of the target pathogen at the on-therapy visit. For analyses greater that 2 ϫ 2, the Cochran-Mantel-Haenszel test was used. Multivariate analysis for bacteriologic and clinical responses was performed with the following variables: geographic region (Israel, United States and Latin America); age (24 months of age and younger or older than 24 months of age); baseline pathogens (single or multiple baseline pathogens); and presence or absence of penicillinnonsusceptible S. pneumoniae. The level of statistical significance was set at P Ͻ 0.05.
RESULTS
Patients
A total of 447 children received at least 1 dose of cefdinir and were included in the safety analysis. The proportions of children treated in Latin America, Israel and the United States were 68, 17 and 15%, respectively. Of these, 217 children were excluded from bacteriologic and bacteriologic/clinical efficacy populations, because of lack of a baseline pathogen (n ϭ 185) and children not returning for the relevant visit (n ϭ 20 at the on-therapy visit and n ϭ 21 at end of treatment, respectively). There were 230 children evaluable at visit 2 for a bacteriologic assessment; and among 230 children with a baseline bacterial pathogen available for visit 3 evaluation, 229 had a end of treatment clinical assessment (clinical and bacteriologically evaluable population).
Demographic and clinical characteristics of the clinically and bacteriologically evaluable population are presented in Table 1 . The majority (74%) of children were 24 months of age or younger; more than one-half had bilateral infection (56%) and more than one-half had received treatment of AOM in the previous 3 months (57%). Children included in Israel were younger (mean age, 13.0 months) than children included in the United States (mean age, 17.5 months) and in Latin America (mean age, 25.8 months) (P Ͻ 0.001).
Microbiology
A total of 266 AOM pathogens were recovered from the MEF of 230 bacteriologically and clinically evaluable children at baseline (15.6% of children had a mixed infection). A total of 125 children had H. influenzae either alone (n ϭ 94) or with S. pneumoniae (n ϭ 23), M. catarrhalis (n ϭ 3), S. pyogenes (n ϭ 1), or S. pneumoniae and M. catarrhalis (n ϭ 4). A total Of the 105 S. pneumoniae isolates with susceptibility results available, 27 (26%) were intermediately susceptible to penicillin (MIC 0.12-1 g/mL) and 23 (22%) were fully resistant to penicillin (MIC Ն2 g/mL). Twenty-one (42%) of the 50 penicillin-nonsusceptible strains of S. pneumoniae were susceptible to cefdinir. All of the 55 penicillin-susceptible strains of S. pneumoniae were susceptible to cefdinir, and 5 of 27 (18.5%) penicillin intermediately resistant to S. pneumoniae had an MIC to cefdinir of Յ0.12 g/mL. None of the 23 penicillin-resistant S. pneumoniae isolates was susceptible to cefdinir. Of the S. pneumoniae isolates with susceptibility results available, 28% (29 of 105) were cefdinir-resistant.
There were regional differences in the penicillin-susceptible S. pneumoniae percentage rates; in Latin America, 70% (42 of 60) of the S. pneumoniae isolates were susceptible to penicillin, whereas in the United States 53% (8 of 15) of isolates and in Israel only 17% (5 of 30) were penicillinsusceptible. There were no regional differences with other target pathogens in terms of cefdinir susceptibility. Bacteriologic Efficacy. Bacteriologic response was determined for 230 evaluable children from whom a target pathogen was isolated at baseline. The overall child bacteriologic eradication rate (at days 4 -6) was 74% (170 of 230) among bacteriologic evaluable children, 70% for children 24 months of age or younger and 86% for children older than 24 months ͓95% confidence interval (95% CI) for difference, Ϫ28.0, Ϫ5.7; P ϭ 0.01͔ (Table 2 ). The study target pathogen eradication rate was 76% (201 of 266) ͓72% in children Յ24 months versus 86% in children older than 24 months of age (95% CI for difference, Ϫ24.7, Ϫ4.0); P ϭ 0.02͔, including 72% (90 of 125) of baseline H. influenzae isolates, 74% (81 of 109) of baseline S. pneumoniae isolates, 92% (21 of 23) of baseline M. catarrhalis isolates and 100% (9 of 9) of baseline S. pyogenes isolates. Bacterial eradication of all organisms was observed among 32% (8 of 25) of children with combined infections with S. pneumoniae and H. influenzae ͓5 of 6 with ␤-lactamase-negative H. influenzae and penicillinsusceptible S. pneumoniae; 2 of 17 with ␤-lactamase-negative H. influenzae and penicillin-nonsusceptible (MIC Ͼ 0.125 g/mL) S. pneumoniae; and 1 of 2 with ␤-lactamase-positive H. influenzae and penicillin-nonsusceptible S. pneumoniae͔.
The overall bacteriologic eradication was also analyzed by participating region; the rates were 83% (114 of 137) for children from Latin America, 89% (34 of 38) for children from the United States and 40% (22 of 55) for children from Israel. Results from a multivariate analysis including all the variables described in the statistical section (geographic region, age, single or multiple pathogens and presence or absence of penicillin-nonsusceptible S. pneumoniae) demonstrated that the 2 variables associated with bacteriologic failures were region (P ϭ Ͻ0.001) and the presence of a penicillin-nonsusceptible S. pneumoniae (P ϭ 0.02). Although not statistically significant, the mean age of those children considered bacteriologic failures was lower in the Israeli participants (mean age, 13.2 months) and the United States participants (mean age, 17.5 months) than in the Latin America children (mean age, 19.0 months) (P ϭ 0.06).
Among all H. influenzae isolates obtained at baseline (alone or combined), eradication rates among ␤-lactamasenegative and -positive strains were 68% (67 of 98) and 90% (18 of 20), respectively (P ϭ 0.03). Bacteriologic eradication was observed among 74% (87 of 118) of cefdinir-susceptible strains and among 33% (1 of 3) a limited number of cefdinirresistant strains.
The overall eradication rate among S. pneumoniae isolates (alone or combined with other pathogens) was 74% (78 of 105). Bacteriologic eradication was 89% (65 of 74) Latin America, 7 of 9 (78%) and 7 of 9 (78%), respectively; the United States, 4 of 4 (100%) and 2 of 3 (67%), respectively; and Israel, 7 of 14 (50%) and 1 of 11 (9%), respectively. Overall eradication rate in penicillin-nonsusceptible versus penicillin-susceptible S. pneumoniae strains was 56% (28 of 50) versus 91% (50 of 55), respectively (P Ͻ 0.001). No significant differences between the study sites were observed in term of bacteriologic eradication when corrected for penicillin MIC. Clinical Efficacy. Clinical cure rates for the clinically and bacteriologically evaluable children are presented in Table 3 . The regional clinical cure rates at end of treatment among the clinically and bacteriologically evaluable children were: 88% (122 of 139) in Latin America; 68% (26 of 38) in the United States; and 77% (41 of 53) in Israel. A multivariate analysis demonstrated that the significant variable for these differences were the presence of a penicillin-nonsusceptible S. pneumoniae isolates (P ϭ 0.048). Clinical cure rates for children with pretreatment negative and positive cultures was 96 and 83%, respectively (P Ͻ 0.001). Clinical cure data are presented by pathogen also in Table 3 .
The overall clinical cure rate for children with baseline H. influenzae (alone or combined) was 82% (103 of 125) at end of treatment and 68% (78 of 114) at end of study (persistent clinical cure). The end of treatment clinical cure rate among children with single H. influenzae infection was 82 of 93 (88%) versus 21 of 32 (66%) clinical cure rates observed in children in which H. influenzae infections was part of a mixed infection (P ϭ 0.004). The overall clinical cure rate for children infected with ␤-lactamase-negative and ␤-lactamase-positive isolates (alone and combined) was 82% (80 of 89) and 80% (16 of 20) , respectively, at end of treatment and 66% (59 of 90) and 72% (13 of 18), respectively, at end of study. Clinical failure rates among children infected with ␤-lactamase-negative and ␤-lactamase-positive isolates alone was 11% (8 of 71) and 16% (3 of 18) (P ϭ 0.68), respectively, and the corresponding values observed in children with combined infections (H. influenzae together with other target pathogen) was 37% (10 of 27) and 50% (1 of 2), respectively. When analyzing the number of clinical failures among children with single or combined H. influenzae infections, the corresponding clinical failure rates was 12% (11 of 89) and 38% (11 of 29) (P ϭ 0.005), respectively, and the Odd ratio for a clinical failure among children with combined infection versus children with single infection was 4.36 (95% CI, 1.63-11.55). The clinical cure rate for those infected with H. influenzae cefdinir-susceptible or -nonsusceptible isolates was 82% (97 of 118) versus 67% (2 of 3), respectively, at end of treatment and 68% (73 of 118) versus 67% (2 of 3), respectively, at end of study.
The overall clinical cure rate among children with baseline S. pneumoniae isolates (alone or combined) was 76% (82 of 108) at end of treatment and 64% (67 of 104) at end of study. Clinical cure at end of treatment was observed among 83% (59 of 71) of children infected with a cefdinirsusceptible strain and among 58% (18 of 31) of children infected with a cefdinir-resistant strain (P ϭ 0.048).
Among children with baseline S. pneumoniae, clinical cure at end of treatment and end of study was analyzed by penicillin susceptibility. At end of treatment, the clinical cure rate among children infected with penicillin-susceptible and penicillin-nonsusceptible isolates was 89% (48 of 54) and 60% (30 of 50), respectively (P ϭ 0.0012). Maintained clinical cure at the end of study was observed in 81% (42 of 52) and 46% (23 of 50) of children, respectively (P ϭ Ͻ 0.001). The data were also analyzed by cefdinir susceptibility. The clinical cure at end of treatment was 60 of 73 (82%) for cefdinir-susceptible S. pneumoniae and 18 of 31 (58%) for cefdinir-nonsusceptible S. pneumoniae (P ϭ 0.008). At the end-of-study visit, the clinical cure rate was 52 of 71 (73%) for cefdinir-susceptible S. pneumoniae and 13 of 31 (42%) for cefdinir-nonsusceptible S. pneumoniae (p 0.004). In children with baseline mixed infections with S. pneumoniae and H. influenzae, clinical cure at end of treatment and end of study was observed in 61% (17 of 28) and 57% (13 of of children with persistent isolates at the on-therapy visit were assigned as clinical failures at the end-of therapy visit (odds ratio, 3.3; 95% CI 1.41, 7.90; P ϭ 0.008).
Safety
The overall incidence of drug-related adverse events was 52% (232 of 447), with abnormal stools (26%), diarrhea (14%) and vomiting (9%) being the most commonly reported events. Most drug-related adverse events were considered mild or moderate, and they resolved rapidly without the need for additional treatment. A minority (9.2%) of children required premature discontinuation of study drug because of a drug-related adverse event(s) (ie, 3 because of vomiting and 1 because of allergic reaction, diarrhea, anxiety, increased alanine aminotransferase/aspartate aminotransferase, somnolence/diarrhea and nausea/abdominal pain/vomiting/dizziness/headache). There were no serious adverse events that were attributed to the study drug. Five (1%) children experienced a serious adverse event unrelated to study drug during their participation in the study (2 each with pneumonia and 1 each with gastrointestinal disorder, gastroenteritis and accidental injury, all leading to hospitalization).
DISCUSSION
Although there are limited data regarding the penetration of cefdinir into the middle ear 26 and therefore the pharmacokinetic and pharmacodynamic characteristics of this compound are difficult to predict, cefdinir has good in vitro activity against most of the bacterial pathogens commonly found in the MEF of children with otitis media, including penicillin-susceptible S. pneumoniae isolates and ␤-lactamase-producing H. influenzae strains. 15, 16 Cefdinir is not approved for the treatment of children infected with penicillin-nonsusceptible S. pneumoniae isolates. 26 The approval of cefdinir was supported by the results of various comparative clinical trials performed in children 6 months-12 years of age with uncomplicated AOM; clinical success reported with this agent was similar to that of comparative agents. [17] [18] [19] [20] [21] [22] Specifically end of treatment clinical success rates observed in previous AOM trials with cefdinir at 14 mg/kg (73-80%) were similar to the clinical success rates observed in our study; furthermore, in one trial that included a baseline tympanocentesis, with the use of cefdinir at 14 mg/kg/d, the per pathogen clinical success was similar to the results observed in the present study with a tendency towards lower success rates in children with penicillin-nonsusceptible S. pneumoniae than among children with penicillin-susceptible S. pneumoniae. 18 Recently the American Academy of Pediatrics and the American Academy of Family Physicians recommended cefdinir as an alternative to amoxicillin for children with uncomplicated AOM who experienced non-type 1 penicillin allergy, and a recent comparative, nontympanocentesis clinical trial suggested that 5 days of treatment with cefdinir (14 mg/kg divided twice daily) was comparable with a 10-day course of low dose amoxicillin/clavulanate. 21, 27 Because of the need for antimicrobial alternatives for treating AOM caused by penicillin-nonsusceptible S. pneumoniae and the lack of information regarding the value of cefdinir in children at risk for infection caused by resistant MEF pathogens, the present study was undertaken. Specifically our objective was to determine microbiologic and clinical responses to cefdinir at a higher dose (25 mg/kg once daily) among children at risk for persistent or recurrent infection, a group most likely to have severe disease and to be difficult to treat.
Although we recognize that using a during-treatment bacteriologic assessment as the primary analysis variable is debatable, there is extensive evidence indicating that children with during-treatment bacterial persistence have a higher rate of clinical failure at the end-of-treatment visit and clinical relapse during the posttreatment follow-up period. 9, 12 These findings were also confirmed in this trial; the odds ratio for end-of-treatment clinical failure was 3 times higher among children in whom a MEF culture was still positive at the on-treatment visit than in those with sterile MEF or no MEF.
H. influenzae was the most common pathogen observed in this population, followed by S. pneumoniae, an observation previously reported even from countries where pneumococcal conjugate vaccines are not routinely used. 8, 9, 28 In this study, 17% of H. influenzae strains produced ␤-lactamase, and 48% of the S. pneumoniae strains were penicillin-nonsusceptible. Although regional differences were observed in the percentage of during-treatment bacteriologic persistence, a multivariate analysis demonstrated that these differences were attributed to the presence of penicillin-resistant S. pneumoniae in both the clinical and bacteriologic response.
The overall bacteriologic eradication rate at the time of the repeated tympanocentesis (on days 4 -6 of treatment) was 76%, with the eradication rate lower in children 24 months of age or younger than in children older than 24 months of age (72% versus 86%, respectively; P ϭ 0.012). This age-related difference in bacterial eradication was mostly related to the higher proportion of penicillin-and cefdinir-nonsusceptible S. pneumoniae causing infection in the younger age group, because for penicillin-and cefdinir-susceptible S. pneumoniae, higher eradication rates were observed in both groups. Eradication rates for M. catarrhalis (92%) and S. pyogenes (100%) were excellent and similar to those seen with other antimicrobial agents. 12, 29 In the case of H. influenzae, bacterial eradication was lower among ␤-lactamase-negative strains (68%) than among ␤-lactamase-positive strains (90%). The relative overall low eradication rate for a third generation cephalosporin against H. influenzae (72%), especially given at a high dose, was unexpected and might have been related to the larger number of children with combined infections in the group of children with ␤-lactamase-negative strains (27 children) than among ␤-lactamase-positive strains (2 children) (P ϭ 0.15), because it was clearly not related to differences in age between children with ␤-lactamase-positive strains (mean age, 19.7 months; SD 15.68) and ␤-lactamase-negative strains (mean age, 19.1 month; SD 11.85) or with any other high risk factor such as number of children with siblings 8 years old or younger (65% versus 73%, respectively; P ϭ 0.62), number of children attending day-care centers (41% versus 50%, respectively; P ϭ 0.61), number of children with Ͼ3 otitis media episodes in the previous 12 months (50% versus 44%, respectively; P ϭ 0.84), number of children with antimicrobial treatment in the previous 3 months for an otitis media episode (65% versus 59%, respectively; P ϭ 0.81). Furthermore the odds ratio for a clinical failure in the case of children with combined infection versus children with single H. influenzae infection was significant (odds ratio, 4.3).
The high cefdinir dose given in this study aimed at better eradication of penicillin-nonsusceptible S. pneumoniae than the standard 14 mg/kg daily dose. However, the eradication rate among penicillin-intermediate (67%) and penicillin-resistant S. pneumoniae (43%) was significantly lower than the eradication observed among penicillin-susceptible strains (91%) and the presence of penicillin-nonsusceptible S. pneumoniae was the most important factor associated with bacteriologic persistence and clinical failures. The relatively low eradication rates among penicillin-nonsusceptible S. pneumoniae isolates despite the higher cefdinir dose used in this trial (25 mg/kg once a day) suggest a limitation for the use of this agent for treating AOM episodes associated with these strains and is in accordance with the current approval of cefdinir for the treatment of otitis media children with penicillin-susceptible S. pneumoniae infections but not penicillinnonsusceptible S. pneumoniae infections.
Recently cefdinir MIC interpretative standard values for S. pneumoniae were modified from the previous penicillin-based values. 25 The bacteriologic and clinical results from our study strongly suggest that the current Clinical and Laboratory Standards Institute interpretation for cefdinirsusceptible (Յ0. The results of this clinical trial are consistent with those of a recently presented pharmacokinetic study. Bowlware et al 30 showed that despite higher C max and area under the curve values obtained with cefdinir 25 mg/kg versus 14 mg/kg once daily, T Ͼ MIC did not exceed Ͼ40% of the cefdinir dosing interval for penicillin-nonsusceptible S. pneumoniae, predicting many bacteriologic and clinical failures. There is a clear need to better characterize the pharmacokinetic and pharmacodynamic profile of cefdinir to fully evaluate whether other dosing regimens can improve the bacteriologic outcome against penicillin-nonsusceptible S. pneumoniae strains.
Among children in whom a follow-up tympanocentesis was performed at the time of clinical failure or the relapse, new pathogens were detected in 58%. This is consistent with previous reports showing that most clinical recurrences are associated with new infections. 31 Similar to previous reports, H. influenzae, alone or in combination, was the most common pathogen detected at the time of the failure or relapse (63%, 12 of 19), and it was interesting to document lower clinical success rates in children when H. influenzae was isolated at baseline with other pathogens than when it was isolated as a single pathogen (P ϭ 0.004). 12, 13, 32 In this study, the high cefdinir dose of 25 mg/kg once daily was generally well-tolerated with most of the adverse events involving the gastrointestinal tract. Abnormal stools, diarrhea and vomiting were the more frequent events and in most of the cases were mild or moderate resolving without the need for additional treatment. The total number of adverse events, particularly gastrointestinal, was higher in the current study than in previous studies with the lower daily dose of 14 mg/kg, and this may be related to a more active surveillance for abnormal stools in our trial or to the increment in the total cefdinir dose. [17] [18] [19] [20] [21] [22] In conclusion, although both bacteriologic and clinical results were excellent for penicillin-susceptible S. pneumoniae, M catarrhalis and S. pyogenes and intermediate for H. influenzae, the reduced bacteriologic and clinical responses to other organisms, especially to penicillin-nonsusceptible S. pneumoniae, do not demonstrate a significant improvement of the high dose cefdinir over the approved daily dose of 14 mg/kg for the treatment of children with AOM at increased risk of persistence or recurrence.
